Welcome to

United Therapeutics Global Medical Affairs

This website is a resource intended for U.S. healthcare professionals only. This site is intended to provide balanced, scientific, and evidence-based answers to unsolicited medical questions. United Therapeutics does not provide medical advice. It is the healthcare professional’s responsibility to use independent clinical judgment when making clinical decisions for individual patients.

This website may include information that has not been approved by the U.S. Food and Drug Administration. For full prescribing information, including indications, contraindications, warnings, precautions, and adverse events, please refer to the approved product labeling.

Are you a U.S. Healthcare professional?

You are now leaving the UnitherMedAffairs.com website.

This link will take you to a site maintained by a third party who is solely responsible for the site’s content. Click CONTINUE to proceed or CLOSE to return to UnitherMedAffairs.com.

CONTINUE

United Therapeutics: The Path to Transforming the Treatment of Rare Diseases

A New Frontier in PH-ILD: ATS 2022 Symposium

Perspectives on Home Initiation of SC Remodulin®

SC=subcutaneous.

Additional Perspectives on Home Initiation of SC Remodulin®

SC=subcutaneous.

PH in ILD: The Clouds are Clearing – CHEST 2022 non-CME Symposium

SC=subcutaneous.